scholarly journals The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?

2017 ◽  
Vol 15 (4) ◽  
pp. 494-503 ◽  
Author(s):  
Jagar Jasem ◽  
Christine M. Fisher ◽  
Arya Amini ◽  
Elena Shagisultanova ◽  
Rachel Rabinovitch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Early Stage ◽  
Recurrence Score ◽  
Early Stage Breast Cancer ◽  
Node Positive

Prevalence and predictors of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 185-185
Author(s):  
Allison W. Kurian ◽  
Christopher Ryan Friese ◽  
Irina Bondarenko ◽  
Reshma Jagsi ◽  
Steven J. Katz
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Early Stage ◽  
Multivariable Analysis ◽  
Recurrence Score ◽  
Early Stage Breast Cancer ◽  
Clinical Indication ◽  
P Value ◽  
Medical Oncologists ◽  
Younger Age

185 Background: A second medical oncology opinion (SMO) may facilitate chemotherapy decision-making. However, little is known about the interplay between SMOs, treatment decision-making and chemotherapy use. Methods: We surveyed women newly diagnosed with early-stage invasive breast cancer and treated in 2013-2014 (response rate 70%), accrued approximately 3 months after surgery through 2 population-based SEER registries (Georgia and Los Angeles), about their experiences with medical oncologists, decision-making, and chemotherapy use. We evaluated demographic, clinical and decisional factors associated with SMO using logistic regression, and evaluated the association between SMO and chemotherapy, adjusting for clinical indication for chemotherapy, results of the 21-gene recurrence score assay, and estimated propensity for SMO given patient and tumor-specific characteristics. Results: Among 1182 insured patients who consulted any medical oncologist, 8.7% had SMO and 2.4% received chemotherapy from the SMO provider. On multivariable analysis, predictors of SMO use were younger age (odds ratio, OR 0.97 per year, 95% confidence interval, CI 0.94-0.99), education (college vs. high school graduate, OR 1.88, CI 1.06-3.33), an intermediate 21-gene recurrence score (OR 2.21, CI 1.18-4.16) and a variant of uncertain significance on BRCA1/2 gene testing (OR 5.61, CI 1.22-25.72). Satisfaction with chemotherapy decision-making was high and did not differ between patients who did vs. did not receive SMO (85.3% quite or totally satisfied vs. 86%, p-value 0.85). On multivariable analysis, chemotherapy use did not differ between SMO recipients vs. non-recipients (p-value 0.25). Conclusions: SMO use was low among early-stage breast cancer patients, and was not followed by more or less receipt of chemotherapy. High decision satisfaction regardless of SMO use suggests little unmet demand. Along with younger age and more education, the factor that predicted SMO use was uncertain results of genomic testing. Studies of precision medicine should track patients’ demand for SMO, which may rise with the dissemination of increasingly complex genomic tests. Funding: P01-CA-163233

scholarly journals Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer

2019 ◽  
Vol Volume 12 ◽  
pp. 2071-2078 ◽  
Author(s):  
San-Gang Wu ◽  
Wen-Wen Zhang ◽  
Jun Wang ◽  
Yong Dong ◽  
Yong-Xiong Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Early Stage ◽  
Recurrence Score ◽  
Early Stage Breast Cancer

Exploring and supporting older women's chemotherapy decision-making in early-stage breast cancer

2021 ◽  
Author(s):  
Meghan S. Karuturi ◽  
Sharon H. Giordano ◽  
Diana S. Hoover ◽  
Robert J. Volk ◽  
Ashley J. Housten
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Early Stage ◽  
Early Stage Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document